|
|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
|
Compact Navigation System for CT-guided Needle Interventions
|
1UT1CA224886-01A1
|
$149,927
|
|
TSE, TSZ HO
|
3T TECHNOLOGIES, LLC
|
|
|
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
|
2R42CA203456-02A1
|
$999,501
|
|
MARATHI, UPENDRA
|
7 HILLS PHARMA, LLC
|
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia
|
5R44CA221539-02
|
$660,235
|
|
RODGERS, BUEL
|
AAVOGEN, INC.
|
|
|
Personalized precision dosing of biologic therapies in oncology
|
5R44CA217336-02
|
$720,363
|
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
|
Image-guided ultrasound ablation for precision targeting of prostate cancer
|
1R01CA230323-01
|
$580,217
|
$580,217
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
|
SBIR PHASE I: ANTIBODY ARRAY FOR CANCER DETECTION
|
N43CN700065-000
|
|
$0
|
BOCHKARIOV, DMITRY
|
ADVANSTA INC
|
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
|
Distance Education to Engage Alaskan Community Health Aides in Cancer Control
|
5R25CA186882-05
|
$135,579
|
|
CUEVA, MELANY
|
ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
|
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis
|
1R01CA222358-01A1
|
$635,306
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Nutritionally Driven Sporadic Intestinal Tumors: Impact on Stem Cells
|
1R01CA229216-01
|
$493,238
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-06
|
$660,173
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$145,846
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Training of Surgeons for Studies of the Tumor Microenvironment
|
5T32CA200561-04
|
$264,583
|
|
MICHLER, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Molecular markers of risk of subsequent invasive breast cancer in women wth ductal carcinoma in situ
|
5R01CA218429-02
|
$1,347,851
|
|
ROHAN, THOMAS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
RCT of An Internet Cessation Program Plus Online Social Network for HIV + Smokers
|
5R01CA192954-05
|
$626,669
|
|
SHUTER, JONATHAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Next Generation of HPV and Cervical Cancer Research in HIV+ Women
|
1R01CA230331-01
|
$670,295
|
|
STRICKLER, HOWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Identification and targeting of pathways separating healthy stem cell aging from malignant transformation
|
1R01CA230756-01
|
$382,013
|
|
WILL, BRITTA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Nemours NCI Community Oncology Research Program (NCORP)
|
5UG1CA189958-05
|
$666,396
|
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
5R44CA183362-03
|
$789,107
|
$394,554
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
|
MicroRNA biomarkers for early detection of prostate cancer
|
1R43CA135917-01
|
$215,621
|
$215,621
|
BROWN, DAVID
|
AMBION DIAGNOSTICS, INC.
|
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S1
|
$2,000
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S2
|
$126,060
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
|
2U01CA098710-05
|
$1,063,219
|
$531,610
|
THUN, MICHAEL
|
AMERICAN CANCER SOCIETY, INC.
|
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S2
|
$9,611,397
|
$4,997,926
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S3
|
$3,952
|
$2,055
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S4
|
$80,640
|
$41,933
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-21S1
|
$27,801
|
$14,457
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-21
|
$1,665,362
|
$865,988
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RTOG Tissue Bank
|
5U24CA114734-04
|
$793,026
|
$79,303
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Total relevant funding to Prostate for this search: $401,826,976
|
